VCM
KRTX

Versant Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Versant Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$651 – 2091
2023
Q2 		$651 Buy
+3
New +$643 ﹤0.01% 1746

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Versant Capital Management's KRTX Position: Q3 2023 in Review

Versant Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 3 shares — an estimated $651 sold.

Versant Capital Management first reported a position in KRTX in Q2 2023 and held it in 1 quarter. The position peaked at $651 in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Versant Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Versant Capital Management sold 3 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $651.
  • Versant Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Versant Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $651 in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Versant Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.